7月13日（路透社）—— 和誉-B（股票代码：2256.HK）宣布，其口服小分子泛KRAS抑制剂ABSK211已获得美国食品药品监督管理局（FDA）的新药临床试验（IND）批准。
此次获批意味着该候选药物已获准在美国开展临床试验，标志着公司在针对KRAS靶点的创新药物研发领域取得了重要进展。KRAS是癌症中常见的突变基因之一，长期以来被视为“不可成药”靶点。ABSK211作为一款泛KRAS抑制剂，旨在靶向多种KRAS突变亚型，为相关癌症患者提供潜在的治疗选择。
公司表示，将积极推进ABSK211的后续临床开发工作。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.